NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Success in a study in essential tremor is marred by a high rate of adverse events and patient dropouts.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.